Vaxcyte’s Pneumococcal Vaccine Exceeds Expectations in Phase 3 Trial

Vaxcyte’s experimental pneumococcal vaccine, VAX-31, has delivered promising results in its first Phase 3 trial, sparking a significant surge in the company’s stock. The vaccine met all primary efficacy goals, demonstrating effectiveness comparable to Pfizer’s Prevnar 20 and Merck’s Capvaxive across nearly all bacterial strains tested in adults aged 50 and older. VAX-31 even outperformed the competitors on three unique strains, though it fell slightly short on two strains when using a stricter statistical threshold. Despite this, analysts and investors viewed the results as a near best-case scenario.

The trial also confirmed that VAX-31 was well tolerated, with safety profiles similar to those of Prevnar 20 and Capvaxive. Most adverse events were mild-to-moderate and resolved quickly. Vaxcyte plans to release results from two additional Phase 3 trials next year and aims for regulatory approval if those results are positive.

Analysts highlighted the significance of VAX-31 as a potential game-changer in the pneumococcal vaccine market, which is dominated by Pfizer’s Prevnar franchise. Mizuho Securities’ Salim Syed described the data as ‘very clean’ and indicative of ‘best-in-class’ potential. Leerink Partners’ David Risinger noted that the misses on two strains under a stricter statistical framework were still impressive and unlikely to impact approval chances.

Vaxcyte’s stock surged by about 50% in early trading, pushing the company’s market value past $12 billion. The results have reinvigorated investor confidence, positioning VAX-31 as a strong contender in a market worth $8 billion annually and growing.